Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers

Summary

This study is a Phase I/IIa, multi-center, open-label study of BR1733 with a dose escalation part followed by a dose expansion part in adult subjects with advanced cancers. This treatment to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment will be administered until the subject experiences unacceptable toxicity, progressive disease, and/or has treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.

Timeline

Start

2023-04-19

Primary completion

2025-05

Completion

2026-05

Drugs

Indications